Epidemiological assessment of SARS-CoV-2 reinfection. (October 2022)

• Record Type: Journal Article
• Authors: Almadhi, Marwa; Alsayyad, Adel Salman; Conroy, Ronan; Atkin, Stephen; Awadhi, Abdulla Al; Al-Tawfiq, Jaffar A.; AlQahtani, Manaf
• Is Part Of: International journal of infectious diseases. Volume 123(2022)
• Page Start: 9
• Page End: 16
• Publication Date: 2022-10
• Subjects: SARS-CoV-2 -- Covid-19 -- Reinfection -- Public health -- Vaccination; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2022.07.075
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Reinfection episodes were highest among those 30-39 years of age Most reinfection episodes occurred ≥9 months after initial infection Most individuals were asymptomatic during both episodes Vaccinated individuals were less likely to have symptomatic reinfection ( P = 0.004) Only 6.6% of reinfection cases required hospitalization, and no deaths were recorded Abstract: Objectives: SARS-CoV-2 vaccination has been shown to reduce infection severity; however, the reinfection frequency among unvaccinated, partially vaccinated, and fully vaccinated individuals remains unclear. This study aims to elucidate the rates of and factors associated with such occurrences. Methods: This retrospective epidemiological report included 1362 COVID-19 reinfection cases in Bahrain between April 2020 and July 2021. We analyzed differences in disease severity and reinfection characteristics among various vaccination statuses: fully vaccinated, interrupted vaccination, one-dose vaccination, postreinfection vaccination, and unvaccinated. Results: Reinfection cases increased from zero per month in April-June 2020 to a sharp peak of 579 in May 2021. A significantly larger proportion of reinfected individuals were male (60.3%, P <0.0001). Reinfection episodes were highest among those 30-39 years of age (29.7%). The fewest reinfection episodes occurred at 3-6 months after the first infection (20.6%) and most occurred ≥9 months after the initial infection (46.4%). Most individuals were asymptomatic during both episodes (35.7%). Reinfection disease severity was mild, with vaccinated patients less likely to have symptomatic reinfection (odds ratio 0.71, P = 0.004). Only 6.6% of reinfected patients required hospitalization. One death was recorded; the patient belonged to the unvaccinated group. Conclusion: Vaccine-induced immunity and previous infection with or without vaccination were effective in reducing reinfection disease severity.